Amy O. Johnson‐Levonas

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia

Harold Bays, Leiv Ose, Neil J. Fraser et al. · Clinical Therapeutics · 2004 · 176 citations

Metabolic Syndrome, Thrombosis, Primary Hypercholesterolemia +12

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Andrew J. Wagner, Udai Banerji, Amit Mahipal et al. · Journal of Clinical Oncology · 2017 · 125 citations · Full text

Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia

Sarah Clauss, Kathryn W. Holmes, Paul N. Hopkins et al. · PEDIATRICS · 2005 · 118 citations

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

John J.P. Kastelein, Joost Besseling, Sukrut Shah et al. · The Lancet · 2015 · 99 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +7

Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib

Ronald M. Krauss, Kathleen Wojnooski, Joseph Orr et al. · Journal of Lipid Research · 2011 · 98 citations · Full text

Metabolic Syndrome, Healthy Individuals, Cardiovascular Disease +8